U.S. markets open in 5 hours 1 minute
  • S&P Futures

    3,843.50
    -5.00 (-0.13%)
     
  • Dow Futures

    30,854.00
    -14.00 (-0.05%)
     
  • Nasdaq Futures

    13,445.00
    -30.50 (-0.23%)
     
  • Russell 2000 Futures

    2,156.20
    -4.80 (-0.22%)
     
  • Crude Oil

    52.74
    -0.03 (-0.06%)
     
  • Gold

    1,852.60
    -2.60 (-0.14%)
     
  • Silver

    25.44
    -0.04 (-0.17%)
     
  • EUR/USD

    1.2132
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.20
    +1.29 (+5.89%)
     
  • GBP/USD

    1.3662
    -0.0013 (-0.10%)
     
  • USD/JPY

    103.7870
    +0.0310 (+0.03%)
     
  • BTC-USD

    31,660.75
    -707.53 (-2.19%)
     
  • CMC Crypto 200

    639.99
    -36.91 (-5.45%)
     
  • FTSE 100

    6,680.75
    +41.90 (+0.63%)
     
  • Nikkei 225

    28,546.18
    -276.11 (-0.96%)
     

Sinovac's vaccine general efficacy less than 60% in Brazil trial - report

BRASILIA, Jan 11 (Reuters) - The CoronaVac COVID-19 vaccine developed by China's Sinovac Biotech has a general efficacy of less than 60% in its clinical trial in Brazil, the news portal UOL reported on Monday, citing two sources that had seen the results.

Sao Paulo's Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report "purely speculative."

(Reporting by Anthony Boadle; Editing by Leslie Adler)